Last reviewed · How we verify
Notch signaling pathway inhibitor MK0752 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Notch signaling pathway inhibitor MK0752 (Notch signaling pathway inhibitor MK0752) — Cancer Research UK.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Notch signaling pathway inhibitor MK0752 TARGET | Notch signaling pathway inhibitor MK0752 | Cancer Research UK | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Notch signaling pathway inhibitor MK0752 CI watch — RSS
- Notch signaling pathway inhibitor MK0752 CI watch — Atom
- Notch signaling pathway inhibitor MK0752 CI watch — JSON
- Notch signaling pathway inhibitor MK0752 alone — RSS
Cite this brief
Drug Landscape (2026). Notch signaling pathway inhibitor MK0752 — Competitive Intelligence Brief. https://druglandscape.com/ci/notch-signaling-pathway-inhibitor-mk0752. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab